- AbbVie (ABBV) said it will incur acquired IPR&D and milestones expenses of $1.3B in its Q4 financial results, leading to a -$0.71 impact to GAAP and non-GAAP diluted EPS.
- The company said its Q4 diluted EPS guidance range, including the impact of the IPR&D and milestones expense, is $2.61-$2.65. Consensus is $2.62.
AbbVie sees negative Q4 EPS impact from IPR&D expenses
